News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myriad Genetics, Inc. (MYGN) Launches myPath™ Melanoma Diagnostic Test


11/12/2013 12:58:08 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched Myriad myPathâ„¢ Melanoma, a new diagnostic test to effectively differentiate malignant melanoma from benign pigmented skin lesions. The myPath Melanoma test has been extensively investigated in two independent clinical studies. Myriad recently presented its verification study results at the American Society of Dermatopathology annual meeting. These data showed that the myPath Melanoma test demonstrated over 90 percent accuracy in differentiating malignant melanoma from benign skin lesions in a variety of subtypes. Results of this study have recently been confirmed in an independent clinical validation study that will be presented at the American Academy of Dermatology in March 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES